TMPO and breast carcinoma: The co-administration of ZER or ZER-HPβCD with TP5-iRGD peptide at three different ratios (1:10, 1:20, and 1:30) wasevaluated after 72 h treatment against MCF-7 and MDA-MB-231 breast cancer cells.